CYTK NASDAQ
Cytokinetics, Incorporated
1W: -3.8%
1M: -7.0%
3M: -21.5%
YTD: -0.3%
1Y: +6.4%
3Y: +85.8%
5Y: +74.2%
$61.52
+0.79 (+1.30%)
Weekly Expected Move ±4.2%
$56
$59
$61
$64
$66
Credit Risk of going bust: lower than 65% of companies Debt: 12.9% of company value Bonds: $54.9M held by 45 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.74 (down 99%), Cytokinetics, Incorporated would be worth roughly what it owes.
Total debt $1.27B against a stock market value of $8.55B.
Distance to default 6.88 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $587.2M (short-term plus half of long-term), stock volatility 42.0%; Altman Z'' -6.09. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.74 (down 99%), Cytokinetics, Incorporated would be worth roughly what it owes.
Total debt $1.27B against a stock market value of $8.55B.
Distance to default 6.88 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $587.2M (short-term plus half of long-term), stock volatility 42.0%; Altman Z'' -6.09. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships6
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-12-20
Earliest Filing
2024-11-19
Latest Filing
partner: 3
investor: 3
Counterparties (Filed by CYTK)
6 relationshipsCompanies named in CYTK's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Bayer Consumer Care AG | — | partner | Exclusive license to develop and commercialize aficamten in Japan | 2024-11-19 | View |
| Bayer | BYMOF | partner | Member of the Bayer Group holding exclusive development license | 2024-11-19 | View |
| Ji Xing Pharmaceuticals Limited | — | partner | Exclusive license and collaboration agreement for omecamtiv mecarbil in greater China | 2021-12-20 | View |
| RTW Master Fund, Ltd. | — | investor | Purchased 511,182 shares of common stock for $20.0 million | 2021-12-20 | View |
| RTW Innovation Master Fund, Ltd. | — | investor | Purchased 511,182 shares of common stock for $20.0 million | 2021-12-20 | View |
| RTW Venture Fund Limited | — | investor | Purchased 511,182 shares of common stock for $20.0 million | 2021-12-20 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-28 | Other Events; Exhibits | View | |
| 2026-08-13 | Other Events | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-05-27 | Shareholder Vote | View | |
| 2026-05-08 | Other Events; Exhibits | View | |
| 2026-05-05 | Other Events; Exhibits | View | |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-02-24 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-17 | Other Events | View | |
| 2025-12-19 | Other Events | View | |
| 2025-12-12 | Other Events | View | |
| 2025-11-14 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-22 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2025-09-16 | Other Events | View | |
| 2025-09-08 | Other Events; Financial Statements and Exhibits | View | |
| 2025-09-03 | Other Events; Financial Statements and Exhibits | View | |
| 2025-09-02 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-20 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR